Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
Emanuel RaschiIgor DiembergerMario SabatinoElisabetta PoluzziFabrizio de PontiLuciano PotenaPublished in: Expert opinion on pharmacotherapy (2022)
Sacubitril/valsartan is a foundation of the pharmacological armamentarium in HFrEF to counteract the neuro-hormonal changes and reverse cardiac remodeling, together with beta-blockers, SGLT2i and mineralocorticoid receptor antagonists. The optimal sequence algorithm is an evolving issue, and the authors provide the reader with their personal perspective. A multidisciplinary management is encouraged to minimize the therapeutic inertia and manage tolerability issues, thus supporting adherence. Pragmatic trials, pharmacovigilance, and high-quality real-world evidence are crucial toward personalized safe prescribing of sacubitril/valsartan.
Keyphrases
- ejection fraction
- aortic stenosis
- heart failure
- left ventricular
- adverse drug
- primary care
- machine learning
- open label
- deep learning
- type diabetes
- study protocol
- polycystic ovary syndrome
- randomized controlled trial
- adipose tissue
- coronary artery disease
- emergency department
- drug induced
- skeletal muscle
- transcatheter aortic valve replacement
- quality improvement
- combination therapy